Stock Events

Stock Events

Puma Biotechnology 

$6.63
0
+$0.02+0.3% Thursday 04:00

Statistics

Day High
6.63
Day Low
6.63
52W High
-
52W Low
-
Volume
510
Avg. Volume
-
Mkt Cap
334.09M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26FebExpected
Q3 2025
Next
0.05
0.09
0.14
0.19
Expected EPS
0.1925
Actual EPS
N/A

Financials

13.14%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
460.94MRevenue
60.56MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PBYI.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG competes in the oncology market, directly challenging Puma Biotechnology's cancer-focused treatments.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca operates in similar therapeutic areas as Puma, including breast cancer treatments, making them direct competitors.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad oncology portfolio that includes breast cancer treatments, competing with Puma's neratinib.
Novartis
NVS
Mkt Cap237.61B
Novartis offers treatments in the oncology sector, including breast cancer, directly competing with Puma's offerings.
Merck
MRK
Mkt Cap214.76B
Merck's extensive research and development in oncology, including breast cancer treatments, positions them as a competitor.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, with its growing oncology portfolio, competes in the same market as Puma Biotechnology.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb's focus on cancer drugs, including breast cancer, makes it a competitor to Puma.
AMGEN
AMGN
Mkt Cap160.66B
Amgen's oncology and hematology portfolio includes treatments that compete with Puma's cancer therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, known for its innovative treatments, competes in the oncology space with Puma.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, offers oncology treatments that rival Puma's products.

About

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Show more...
CEO
Mr. Alan H. Auerbach
Employees
172
Country
US
ISIN
US74587V1070

Listings

XNAS
US
PBYI
BOATS
BOATS
PBYI.BOATS

0 Comments

Share your thoughts

FAQ

What is Puma Biotechnology stock price today?▼
The current price of PBYI.BOATS is $6.63 USD — it has increased by +0.3% in the past 24 hours. Watch Puma Biotechnology stock price performance more closely on the chart.
What is Puma Biotechnology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Puma Biotechnology stocks are traded under the ticker PBYI.BOATS.
What is Puma Biotechnology market cap?▼
Today Puma Biotechnology has the market capitalization of 334.09M
When is the next Puma Biotechnology earnings date?▼
Puma Biotechnology is going to release the next earnings report on February 26, 2026.
What were Puma Biotechnology earnings last quarter?▼
PBYI.BOATS earnings for the last quarter are 0.17 USD per share, whereas the estimation was 0.05 USD resulting in a +277.78% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Puma Biotechnology revenue for the last year?▼
Puma Biotechnology revenue for the last year amounts to 460.94M USD.
What is Puma Biotechnology net income for the last year?▼
PBYI.BOATS net income for the last year is 60.56M USD.
How many employees does Puma Biotechnology have?▼
As of February 02, 2026, the company has 172 employees.
In which sector is Puma Biotechnology located?▼
Puma Biotechnology operates in the Health Care sector.
When did Puma Biotechnology complete a stock split?▼
Puma Biotechnology has not had any recent stock splits.
Where is Puma Biotechnology headquartered?▼
Puma Biotechnology is headquartered in Los Angeles, US.